key: cord-0851050-xoaxpvg8 authors: Saravi, Seyed Soheil Saeedi; Beer, Jürg H. title: Apelin-potential therapy for COVID-19? date: 2020-06-18 journal: J Mol Cell Cardiol DOI: 10.1016/j.yjmcc.2020.06.007 sha: 300f3d9d71b6f665d11c7489e4be627edc52dc30 doc_id: 851050 cord_uid: xoaxpvg8 We believe that, in parallel to the attempts for direct blockade of the SARS-CoV-2 penetration into host cell and repurposing drugs, finding new therapeutic strategies for patients with lung injury or cardiovascular complications/coagulopathies associated with COVID-19 should be paid particular attention. Apelin or its receptor agonists are of great potential treatment for COVID-19 through suppressing angiotensin-converting enzyme (ACE) and angiotensin II (Ang-II) production, as well as, down-regulating angiotensin receptor 1 (AT1R) and ACE2 up-regulation. These drugs have potential to improve acute lung injury and cardiovascular/coagulopathy complications in COVID-19 which are associated with elevated Ang-II/Ang(1–7) ratio. Since December 2019, the novel coronavirus (SARS-CoV-2) was identified in the pneumonia cases of unknown etiology in Wuhan, China, and is rapidly spreading around the world. Given the rapid spread and strong transmissibility of SARS-CoV-2, the epidemiologic picture is varying on a daily basis. The respiratory symptoms including acute respiratory distress syndrome (ARDS) has been recognized as the major cause of death in the patients infected with SARS-CoV-2, and the mortality remains very high despite the different therapeutic regimens including repurposed antivirals, anti-inflammatory agents, and immunomodulators. Scientific evidence is lacking in many domains as Coronavirus disease 2019 (COVID-19) is a novel disease and comprehensive knowledge of pathophysiology remains incomplete. So far, drug repurposing and potential pharmaceutical treatments such as antiretroviral lopinavir-ritonavir, and antimalarial hydroxychloquine and chloroquine, the drugs thought to be the prospects for treating Covid-19, failed to have any effect in the first trials, whereas may even raise the risk of mortality. Therefore, finding potential therapeutic targets for COVID-19 can be timely and of greatest importance to improve clinical outcome and reduce mortality. The renin-angiotensin system (RAS) is a key mechanism underlying ARDS and cardiovascular diseases, so that the recent clinical findings from SARS-CoV-2infected humans and previous studies of SARS-CoV spike protein-infected mice demonstrate the activation of the RAS and remarkable increased serum Ang-II have strongly bind ACE2 for host cell entry and down-regulate ACE2 expression that leads to excessive Ang-II formation and the subsequent ALI [1] . This might be the rationale for the ongoing clinical trials of recombinant human ACE2 (rhACE2) for coronavirus-associated ALI and the cardiovascular/coagulation complications [2] . Therefore, an appropriate therapeutic strategy for improving the lung injury and adverse cardiovascular outcome in COVID-19 could be the suppression of the RAS by simultaneous inhibiting Ang-II production and AT1R and activating ACE2. ACE2 is a key counter-regulator of the RAS and has considerable homology to ACE that exhibits 42% sequence identity and 61% sequence similarity to ACE within the C-terminal domain [3] . Both ACE, the enzyme that converts Ang-I to Ang-II, and ACE2 are expressed and abundant in the human alveolar epithelial cells and extrapulmonary organs including the heart and endothelium. ACE2 also acts as the essential receptor for some respiratory viruses including SARS-CoV-2 and SARS-CoV, through which the viruses gain entry to host cells [1, 4, 5] . Binding of SARS-CoV-2 spike protein to ACE2 followed by the proteolytic cleavage of ACE2 by transmembrane serine protease 2 (TMPRSS2) leads to increased internalization and shedding of ACE2 from cell surface, and consequently decreased Ang(1-7)/Ang-II ratio [5] . Accordingly, down-regulation or severely impaired activity of ACE2, along with dominant increase in ACE activity and the subsequent Ang-II formation have been seen in patients with ARDS [1] . The elevated Ang-II binds its receptor AT1R that can cause severe adverse effects including (1) a rapid vasoconstriction and limited pulmonary circulation, leading to vascular permeability and pulmonary edema in hypoxic condition; (2) boost inflammatory responses; (3) enhanced reactive oxygen species (ROS) production, (4) accelerated apoptotic pathways, and (5) J o u r n a l P r e -p r o o f Journal Pre-proof promoted pulmonary fibrotic events [6] . The excessive Ang-II promotes vascular inflammation through the enhancement of adhesion molecules, pro-inflammatory cytokines and chemokines which may also contribute to the hypercoagulable state and endothelial dysfunction. Moreover, activation of the RAS stimulates transcription factor NF-κB which converts the normal anticoagulant endothelium into a procoagulant surface, expressing tissue factor (TF) with activated plasminogen activator inhibitor-1 (PAI-1) [7] . Apelin peptides are endogenous ligands of the G protein-coupled receptor APJ, which presents in vascular endothelial cells and, particularly, lung tissue. Apelin is a well characterized cardioprotective peptide in the late stages of heart failure, thereby exogenous administration of apelin can augment cardiac output and contractility in the failing hearts and consequently improve the cardiac performance [8] . Previous in vitro and in vivo studies have exhibited the apelin-APJ system counteracts the effects of ACE-Ang-II-AT1R axis and exogenous apelin negatively regulates the RAS. Given that the SARS-CoV-2 infection induces ACE2 down-regulation and consequently activation of ACE and Ang-II signaling, it is predictable that apelin has potential of alleviating the respiratory and cardiovascular complications through upregulating ACE2, which itself enhances Ang(1-7)/Ang-II ratio and suppresses Ang-II signaling. On the other hand, ACE2 up-regulation may increase the risk for susceptibility to SARS-CoV-2 infection, therefore apelin or its analogues are proposed to be used in the late stages of COVID-19 when the viral load is reduced. Even tough, the recent findings elucidate that ACE inhibitors and AT1R blockers, which were presumed to up-regulate ACE2, would not predispose to viral infection J o u r n a l P r e -p r o o f Journal Pre-proof and severity of COVID-19, but were associated with significantly lower expression of ACE2 and the viral entry cofactor TMPRSS2 [9] [10] [11] . The recent cohorts of COVID-19 patients confirm that hypertension and other cardiovascular diseases are comorbidities in almost one-third of the cases who developed ARDS [12] . Experimental and clinical studies suggest that Ang-II mediates inflammation systemically in the lung, heart, and vascular endothelial cells. Moreover, ACE2, the receptor for the SARS coronavirus, was identified as a regulator of acute lung injury, and heart failure [13]. Since SARS-CoV-2 binds and down-regulates ACE2 and consequently activates Ang-II-mediated pathological pathways in the endothelial and epithelial cells in the lung, heart and vasculature, apelin is assumed to play a critical role in alleviating Ang-II-mediated acute lung and cardiovascular injuries and prothrombotic events in COVID-19 patients. Although there is absence of basic and clinical evidence on therapeutic effects of apelin or its analogues on COVID-19 infection and the associated severe complications, preclinical studies to date demonstrate that these peptides are able to ameliorate the severity of ALI by reducing lung fluid accumulation, cytokine secretion, and hypoxemia, which occur in COVID-19-associated ARDS, and lead to downstream injury to the heart, kidney, and other organs [14] . Therefore, these peptides may potentially block acute effects of COVID-19, and their beneficial effects may extend to protecting other organs from the cytokine storm and reducing mortality. Angiotensin-converting enzyme 2 inhibits lung injury induced by respiratory syncytial virus Recombinant human angiotensin-converting enzyme 2 (rhACE2) as a treatment for patients with COVID-19 (APN01-COVID-19) A Human Homolog of Angiotensin-converting Enzyme Controversies of renin-angiotensin system inhibition during the COVID-19 pandemic COVID-19 and the cardiovascular system Recombinant human ACE2: acing out angiotensin II in ARDS therapy The prothrombotic paradox of hypertension Acute Cardiovascular Effects of Apelin in Humans SARS-CoV-2 receptor ACE2 gene expression and RAAS inhibitors Association of Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Cardiovascular considerations for patients, health care workers, and health systems during the Coronavirus disease 2019 (COVID-19) Pandemic Apelin is a positive regulator of ACE2 in failing hearts The Apelin-APJ axis is an endogenous counterinjury mechanism in experimental acute lung injury Apelin, Elabela/Toddler, and biased agonists as novel therapeutic agents in the cardiovascular system Apelin Protects Against Angiotensin II-Induced Cardiovascular Fibrosis and Decreases PAI-1 Production COVID-19 pneumonia: a random association? Eur Design, characterization, and first-in-human study of the vascular actions of a novel biased apelin receptor agonist Cardiac action of the first G protein biased small molecule apelin agonist The authors declare that there is no conflict of interest.